MDT vs SGHT
MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries. SGHT: Sight Sciences develops minimally invasive interventional devices for glaucoma and dry eye, targeting ophthalmology markets through reimbursement-focused commercialization.
Side-by-side fundamentals
| Metric | MDT | SGHT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $84.22 | $5.12 | |
| Market cap as of 2026-07-30 | $107.8B | $279M | |
| P/E as of 2026-07-30 | 23.27 | n/a | |
| PEG as of 2026-07-30 | 2.90 | n/a | |
| Net margin as of 2026-07-30 | +13.2% | -46.8% | MDT higher |
| Gross margin as of 2026-07-30 | +65.3% | +86.9% | SGHT higher |
| Operating margin as of 2026-07-30 | +17.8% | -44.8% | MDT higher |
| ROE as of 2026-07-30 | +9.8% | -59.1% | MDT higher |
| ROA as of 2026-07-30 | +5.2% | -32.2% | MDT higher |
| Debt / equity as of 2026-07-30 | 0.57 | 0.75 | MDT lower |
| Revenue growth (YoY) as of 2026-07-30 | +8.4% | +1.9% | MDT higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +2.7% | MDT higher |
| Dividend yield as of 2026-07-30 | +3.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-30 | 0.54 | 2.46 | |
| 1-year return as of 2026-07-27 close | -9.4% | +46.7% | SGHT higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.